Colombia is celebrating huge price reductions for Gilead Sciences Inc.’s Harvoni (sofosbuvir plus ledispavir) and a combination of Bristol-Myers Squibb Co.’s Daklinza (daclatasvir) and Gilead’s Sovaldi (sofosbuvir), thanks to a joint purchasing initiative backed by the Pan American Health Organization (PAHO).
The cost of the Daklinza/Sovaldi combination in Colombia will go from Pesos 137.2m ($46,069) to Pesos 29m ($9,728) per person....







